Zhang Ji, Xiao XiaoJuan, Liu Jing
Department of Hematology, The First Affiliated Hospital, University of South China, Hengyang, 421001, China.
State Key Laboratory of Medical Genetics & School of Life Sciences, Central South University, Changsha, 410078, China.
Sci China Life Sci. 2015 Dec;58(12):1262-9. doi: 10.1007/s11427-015-4969-2. Epub 2015 Nov 25.
Multiple myeloma (MM) is a common malignant hematological disease. Dysregulation of microRNAs (miRNAs) in MM cells and bone marrow microenviroment has important impacts on the initiation and progression of MM and drug resistance in MM cells. Recently, it was reported that MM patient serum and plasma contained sufficiently stable miRNA signatures, and circulating miRNAs could be identified and measured accurately from body fluid. Compared to conventional diagnostic parameters, the circulating miRNA profile is appropriate for the diagnosis of MM and estimates patient progression and therapeutic outcome with higher specificity and sensitivity. In this review, we mainly focus on the potential of circulating miRNAs as diagnostic, prognostic, and predictive biomarkers for MM and summarize the general strategies and methodologies for identification and measurement of circulating miRNAs in various cancers. Furthermore, we discuss the correlation between circulating miRNAs and the cytogenetic abnormalities and biochemical parameters assessed in multiple myeloma.
多发性骨髓瘤（MM）是一种常见的恶性血液疾病。MM细胞和骨髓微环境中微小RNA（miRNA）的失调对MM的发生发展以及MM细胞的耐药性具有重要影响。最近，有报道称MM患者的血清和血浆中含有足够稳定的miRNA特征，并且可以从体液中准确识别和测量循环miRNA。与传统诊断参数相比，循环miRNA谱更适合MM的诊断，并且能够以更高的特异性和敏感性评估患者的病情进展和治疗效果。在本综述中，我们主要关注循环miRNA作为MM诊断、预后和预测生物标志物的潜力，并总结在各种癌症中识别和测量循环miRNA的一般策略和方法。此外，我们还讨论了循环miRNA与多发性骨髓瘤中评估的细胞遗传学异常和生化参数之间的相关性。
